Session » Genetics, Genomics & Proteomics Poster

Date: Friday, November 6, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM: Abstract Number: 0032

A Prospective, Multicenter, Clinical Performance Evaluation Study for an in-vitro Diagnostics Medical Device (PREDYSTIC® Infliximab RA) for Prediction of Infliximab Responsiveness in the Treatment of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0041

Association of the RPA3-UMAD1 Locus with Interstitial Lung Diseases Complicated with Rheumatoid Arthritis in Japanese

9:00AM-11:00AM: Abstract Number: 0035

Distinct Biological Pathways in Both Blood and Kidney Further Define Molecular Profiles Across Diverse Nephritides

9:00AM-11:00AM: Abstract Number: 0030

Distinct DNA Methylation Patterns of Rheumatoid Arthritis Peripheral Blood and Synovial Tissue T Cells

9:00AM-11:00AM: Abstract Number: 0034

Gene Expression Signatures in C-Reactive Protein High and Low Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0039

Identification of a Regulatory Pathway Governing Expression of TRAF1 via a JIA-associated Non-coding Variant

9:00AM-11:00AM: Abstract Number: 0037

Lipoprotein-associated Phospholipase A2: A New Biomarker for Lymphoma Development in Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 0031

Metabolomics Profiling Predicts Outcome of Tocilizumab in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0036

Molecular Phenotyping of Late-Stage Knee Osteoarthritis Synovium Through Total RNA-Sequencing

9:00AM-11:00AM: Abstract Number: 0033

Pre-pregnancy Long Non-coding RNA Expression Signatures Among Women with Rheumatoid Arthritis Who Improve or Worsen During Pregnancy

9:00AM-11:00AM: Abstract Number: 0038

Protein Biomarkers May Differentiate Responders and Non-Responders to Adalimumab, a Tumour Necrosis Factor Inhibitor, in Ankylosing Spondylitis Patients – The Bioefficacy SpA Study

9:00AM-11:00AM: Abstract Number: 0029

Urine Proteomic Classifiers Predict Renal Histological Activity and Chronicity Indices and May Predict Treatment Response in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 0040

Whole Blood RNA Expression in Clinically Suspected Arthralgia Patients Shows a Potential Value in Prediction of Inflammatory Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].